SG Americas Securities LLC Cuts Stock Position in Illumina, Inc. (NASDAQ:ILMN)

SG Americas Securities LLC lessened its stake in Illumina, Inc. (NASDAQ:ILMN) by 93.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,582 shares of the life sciences company’s stock after selling 22,245 shares during the period. SG Americas Securities LLC’s holdings in Illumina were worth $206,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ILMN. Primecap Management Co. CA grew its stake in Illumina by 462.5% in the second quarter. Primecap Management Co. CA now owns 2,428,760 shares of the life sciences company’s stock valued at $253,514,000 after purchasing an additional 1,997,010 shares during the last quarter. Millennium Management LLC grew its stake in shares of Illumina by 305.0% during the second quarter. Millennium Management LLC now owns 1,485,599 shares of the life sciences company’s stock worth $155,067,000 after acquiring an additional 1,118,747 shares during the last quarter. Capital World Investors grew its stake in shares of Illumina by 41.1% during the first quarter. Capital World Investors now owns 2,753,504 shares of the life sciences company’s stock worth $378,111,000 after acquiring an additional 801,814 shares during the last quarter. Marshall Wace LLP purchased a new stake in shares of Illumina during the second quarter worth about $77,628,000. Finally, Findlay Park Partners LLP purchased a new stake in shares of Illumina during the first quarter worth about $100,120,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Trading Down 0.8 %

Illumina stock opened at $144.06 on Wednesday. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 1.04. Illumina, Inc. has a 12 month low of $89.00 and a 12 month high of $151.40. The stock’s 50 day simple moving average is $133.63 and its two-hundred day simple moving average is $121.35. The firm has a market cap of $22.95 billion, a PE ratio of -17.68 and a beta of 1.15.

Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, August 6th. The life sciences company reported $0.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.12 by $0.24. Illumina had a positive return on equity of 3.08% and a negative net margin of 68.73%. The firm had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.09 billion. During the same quarter last year, the firm posted $0.32 EPS. The business’s revenue was down 5.4% on a year-over-year basis. Analysts anticipate that Illumina, Inc. will post 3.63 earnings per share for the current year.

Wall Street Analyst Weigh In

ILMN has been the topic of a number of research analyst reports. Leerink Partners boosted their price target on Illumina from $160.00 to $200.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. Citigroup boosted their price target on Illumina from $140.00 to $155.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Daiwa Capital Markets raised Illumina from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $120.00 to $154.00 in a report on Friday, August 16th. StockNews.com began coverage on Illumina in a report on Thursday, August 29th. They set a “buy” rating for the company. Finally, Barclays lifted their target price on Illumina from $125.00 to $135.00 and gave the stock an “equal weight” rating in a report on Tuesday, October 15th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $154.33.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.